Who
Geoffrey Ling
Director
Company insider
Files Form 4 as: Director, Celularity; Director, Gyre Therapeutics.
In numbers
- Trades disclosed
- 23
- Buys
- 1
- Sells
- 0
- Bought
- $19K
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 2
- First trade
- 15 Jan 2020
- Last trade
- 12 Jan 2026
- Last filed
- 15 Jan 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 12 Jan 2026filed 15 Jan 2026 | CELU CelularityBiotechnology | SEC FORM 4 Code A | —19,231 at $0.00 | filing |
| 12 Jan 2026filed 15 Jan 2026 | CELU CelularityBiotechnology | SEC FORM 4 Code A | —19,231 at $0.00 | filing |
| 12 Jan 2026filed 14 Jan 2026 | CELU CelularityBiotechnology | SEC FORM 4 Code A | —19,231 at $0.00 | filing |
| 12 Jan 2026filed 14 Jan 2026 | CELU CelularityBiotechnology | SEC FORM 4 Code A | —19,231 at $0.00 | filing |
| 29 Dec 2025filed 30 Dec 2025 | CELU Celularityoption or derivative · Biotechnology | SEC FORM 4 Code A | —156,250 at $0.00 | filing |
| 29 Dec 2025filed 30 Dec 2025 | CELU CelularityBiotechnology | SEC FORM 4 Code A | —125,000 at $0.00 | filing |
| 19 Dec 2025filed 22 Dec 2025 | CELU CelularityBiotechnology | SEC FORM 4 Code A | —67,416 at $0.00 | filing |
| 19 Nov 2025filed 21 Nov 2025 | CELU CelularityBiotechnology | SEC FORM 4 Code A | —44,379 at $0.00 | filing |
| 19 Dec 2024filed 6 Jan 2025 | CELU Celularityoption or derivative · Biotechnology | SEC FORM 4 Code A | —84,746 at $0.00 | filing |
| 19 Dec 2024filed 6 Jan 2025 | CELU CelularityBiotechnology | SEC FORM 4 Code A | —67,416 at $0.00 | filing |
| 31 Aug 2023filed 16 Oct 2023 | CELU Celularityoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,250,000 at $0.00 | filing |
| 7 Jan 2022filed 7 Jan 2022 | GYRE Gyre TherapeuticsBiotechnology | SEC FORM 4 Code A | —12,855 at $0.00 | filing |
| 1 Oct 2021filed 5 Oct 2021 | GYRE Gyre TherapeuticsBiotechnology | SEC FORM 4 Code A | —2,858 at $0.00 | filing |
| 1 Jul 2021filed 2 Jul 2021 | GYRE Gyre TherapeuticsBiotechnology | SEC FORM 4 Code A | —2,713 at $0.00 | filing |
| 9 Jun 2021filed 2 Jul 2021 | GYRE Gyre Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —14,000 at $0.00 | filing |
| 1 Apr 2021filed 5 Apr 2021 | GYRE Gyre TherapeuticsBiotechnology | SEC FORM 4 Code A | —2,331 at $0.00 | filing |
| 5 Jan 2021filed 6 Jan 2021 | GYRE Gyre TherapeuticsBiotechnology | SEC FORM 4 Code A | —1,782 at $0.00 | filing |
| 1 Oct 2020filed 2 Oct 2020 | GYRE Gyre TherapeuticsBiotechnology | SEC FORM 4 Code A | —2,616 at $0.00 | filing |
| 1 Jul 2020filed 2 Jul 2020 | GYRE Gyre TherapeuticsBiotechnology | SEC FORM 4 Code A | —1,703 at $0.00 | filing |
| 11 Jun 2020filed 12 Jun 2020 | GYRE Gyre Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,000 at $0.00 | filing |
News
Gyre Therapeutics (NASDAQ:GYRE) vs. GSK (NYSE:GSK) Head-To-Head ContrastGYRE · dailypolitical.com · 19 Oct 2026GSK (NYSE:GSK) versus Gyre Therapeutics (NASDAQ:GYRE) Financial ContrastGYRE · themarketsdaily.com · 15 Oct 2026Contrasting Scienture (NASDAQ:SCNX) & Gyre Therapeutics (NASDAQ:GYRE)GYRE · themarketsdaily.com · 13 Oct 2026
0 headlines in the last 90 days name Geoffrey Ling; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.